Search - tctmd.com

Displaying 21 - 40 of 40

Sort: Relevancy | Date

Presentation TCT 2022

TCT 577: Lipoprotein (a) and Intracoronary Imaging After Intensive Statin Treatment

Presenter: Shingo Minatoguchi

September 19, 2022

Presentation TCT 2022

TCT 576: Serum Cholesterol Levels Do Not Influence Lipid Core Burden Index

Presenter: Frans Mensink

September 19, 2022

Presentation TCT 2022

The Importance of Addressing Lipids in Patients With Complex PCI

Presenter: Nisha Jhalani

September 19, 2022

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

Presentation TCT 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presenter: Aloke Finn

September 28, 2019

Presentation TCT 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presenter: Ziad Ali

September 28, 2019

Presentation TCT 2019

What is the Role of the Interventional Cardiologist in Lipid Management?

Presenter: Wolfgang Koenig

September 28, 2019

Presentation TCT 2019

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

Presenter: R. Wright

September 28, 2019

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes After Stent Implantation in Patients With Coronary Artery Disease

Presenter: Howard C. Herrmann, Robert J. de Winter, Giora Weisz

November 01, 2016

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Conference News TCT 2015

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

Yael L. Maxwell

October 16, 2015

Presentation TCT 2013

Release of Bioactive Lipids During Percutaneous Coronary, and Peripheral Arterial Interventions in Humans: Lipidomic analysis of Distal Embolic Protection Devices.

Presenter: Amir Ravandi, Gregor Leibundgut, Patrick Hu, Anand Prasad, Brian Kolski, Bahram Khadivi, Mitul Patel, Ehtisham Mahmud, Yury Miller, Edward Dennis, Joseph Witztum, Sotirios Tsimikas

January 31, 2013

Presentation TCT 2013

Nicorandil Prevents Microvascular Dysfunction Resulting from Percutaneous Coronary Intervention in Patients with Stable Angina Pectoris

Presenter: Atsushi Hirohata, Eiki Hirose, Yuhei Kobayashi, Minako Ohara, Tohru Ohe, Fumihiko Sano, Hiroya Takafuji, Hiroyuki Takinami, Keizo Yamamoto, Ryo Yoshioka

January 31, 2013

Presentation TCT 2013

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Presenter: Subhash Banerjee, Rick Weideman, Bertis Little, Mark Weideman, Jennifer Gunter, Kevin Kelly, Emmanouil Brilakis

January 31, 2013

Presentation TCT 2013

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

Presenter: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Amro Elnagar, Sung Il Im, Sun Won Kim, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong

January 31, 2013

Presentation TCT 2012

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

Presenter: Josef Veselka

October 22, 2012

Presentation TCT 2012

Atorvastatin, Administered at the Onset of Reperfusion, Protects Human Myocardium Against Lethal Reperfusion Injury by Activation of the RISK pathway

Presenter: Paul S. Rees, Derek J. Hausenloy, Derek M. Yellon

January 03, 2012

Advertisement

TCT 577: Lipoprotein (a) and Intracoronary Imaging After Intensive Statin Treatment

TCT 576: Serum Cholesterol Levels Do Not Influence Lipid Core Burden Index

The Importance of Addressing Lipids in Patients With Complex PCI

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

What is the Role of the Interventional Cardiologist in Lipid Management?

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes After Stent Implantation in Patients With Coronary Artery Disease

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

Release of Bioactive Lipids During Percutaneous Coronary, and Peripheral Arterial Interventions in Humans: Lipidomic analysis of Distal Embolic Protection Devices.

Nicorandil Prevents Microvascular Dysfunction Resulting from Percutaneous Coronary Intervention in Patients with Stable Angina Pectoris

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Can Amelioration of HDL-C Level by Pitavastatin Improve Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention?

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

Atorvastatin, Administered at the Onset of Reperfusion, Protects Human Myocardium Against Lethal Reperfusion Injury by Activation of the RISK pathway

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content